

+

+

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



**Complete if Known**

<b>Application Number</b>	<b>09/711,709</b>
<b>Filing Date</b>	<b>November 13, 2000</b>
<b>First Named Inventor</b>	<b>Moshe Kushnir et al.</b>
<b>Group Art Unit</b>	<b>1616</b>
<b>Examiner Name</b>	<b>M.A. Williamson</b>
<b>Attorney Docket Number</b>	<b>287985/009 (LR/MCD/YL)</b>

*(use as many sheets as necessary)*

Sheet	1	of	2	Attorney Docket Number	287985/009 (LR/MCD/YL)
-------	---	----	---	------------------------	------------------------

[illegible]

RECEIVED  
JUL 8 0 2002  
TECH CENTER 1600/2900

[illegible]

Examiner  
Signature

Williamson

Date \_\_\_\_\_

**Considered**

9/02

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

SSL-DOCS1 1212115.03

+

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

### Complete if Known

Application Number	09/711,709
Filing Date	November 13, 2000
First Named Inventor	Moshe Kushnir et al.
Group Art Unit	1616
Examiner Name	M.A. Williamson
Attorney Docket Number	287985/009 (LR/MCD/YL)

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
UAW		International Search Report dated 10 February 1998.
		Cooper DR, et al. L-Dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease. J. Pharm. Pharmacol. 1987, 39:627-635.
		Fix JA, et al. Short-Chain Alkyl Esters of L-Dopa as Prodrugs for Rectal Absorption. Pharmaceutical Research. 6 (6):501-505 (1989).
		Fix JA, et al. A Comparison of Oral and Rectal Absorption of L-Dopa Esters in Rats and Mice. Pharmaceutical Research. 7(4):384-387 (1990).
		Marrel C, et al. L-DOPA esters as Potential prodrugs. Part. II. Chemical and enzymatic hydrolysis. Eur. J. Med. Chem. - Chem. Ther., 1985-20 No. 5, pp. 467-470.
		Stocchi F, et al. Intravenous Boluses and Continuous Infusions of L-Dopa Methyl Ester in Fluctuating Patients with Parkinson's disease. Move Disorders, V. 7, No. 3, 1992, pp. 249-256.
		Chemical Abst., CAS Reg. No. 59-92-7 (2000 ACS)
		Chemical Abst., CAS Reg. No. 37178-37-3 (2000 ACS)
		Djaldetti R. et al. Levodopa ethylester: A novel rescue therapy for response fluctuations in Parkinson's disease. Ann. Neurol. (1996), 39(3), 400-4.
UAW		Ahmed, Ghulam, et al. Facile synthesis of L-Dopa esters by combined use of tyrosinase and .alpha.-chymotrypsin. Biotechnol. Lett. (1994), 16(4), 367-72.

Examiner Signature

UAW

Date

Considered

9/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.